Skip to main content
SpringerLink
Log in

Lower OOP costs do not reduce access to DMT in MS

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Shao H, et al. Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs' Access in Multiple Sclerosis. Value in Health : 8 Jan 2018. Available from: URL: https://doi.org/10.1016/j.jval.2017.10.025

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lower OOP costs do not reduce access to DMT in MS. PharmacoEcon Outcomes News 795, 17 (2018). https://doi.org/10.1007/s40274-018-4655-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4655-2

Search

Navigation